SRT1720 HCl

Catalog No.S1129

For research use only.

SRT1720 HCl is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3. SRT1720 induces autophagy.

SRT1720 HCl Chemical Structure

CAS No. 1001645-58-4

Selleck's SRT1720 HCl has been cited by 157 publications

Purity & Quality Control

Choose Selective Sirtuin Inhibitors

Other Sirtuin Products

Biological Activity

Description SRT1720 HCl is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3. SRT1720 induces autophagy.
Targets
SIRT1 [1]
(Cell-free assay)
0.16 μM(EC50)
In vitro

The maximum activation ratio of SRT1720 versus the closest sirtuin homologues, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%. SRT1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. SRT1720 could reduce fed glucose levels. Glucose excursion during an intraperitoneal glucose tolerance test is also significantly reduced in the SRT1720 group, and comparable to rosiglitazone, a PPARγ activator that has been used to treat type 2 diabetes. SRT1720 does not have an effect on fasting glucose in chow-fed mice, revealing that pharmacological SIRT1 activation is unlikely to induce hypoglycaemia. SRT1720 significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing increased insulin levels similar to rosiglitazone treatment. SRT1720 treatment increases mitochondrial capacity by 15% in gastrocnemius muscle as measured by citrate synthase activity. [1] Higher concentrations of SRT1720 (15 μM) induces a modest (10-20%) decrease in normal cell viability. SRT1720 also significantly inhibits VEGF-dependent MM cell migration. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CACs  NUfLWVY2TnWwY4Tpc44hSXO|YYm= NX21NlZPPMLizszN NV\HTpZ[OzEEoH3pci=> MljRSG1UVw>? Mn;LbY5lfWOnczDhZ5V1\SCVSWLUNUBi[3SrdnH0bY9vyqB? MlK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUSxNFQoRjJ4MkW0NVA1RC:jPh?=
MC3T3-E1 MUDGeY5kfGmxbjDBd5NigQ>? NXvKXZoyOTBiwsXNxsA> MX2xJIg> MYHy[YR2[2W|IITo[UBVT0ZvzsKtd5RqdXWuYYTl[EBXTUeIIILlcIVie2ViaX6g[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5mesLi NUK5PZAxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|Y6PzhpPkK2NVM3QTd6PD;hQi=>
MC3T3-E1 M3e1TmZ2dmO2aX;uJGF{e2G7 NIPweI4yOCEEtV5CpC=> NGTqT4UyOiCq MofWdoVlfWOnczD0bIUhXkWJRjDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KHO2aX31cIF1\WRiYomgWGdHNc7{ M{\PZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO2PVc5Lz5{NkGzOlk4QDxxYU6=
MC3T3-E1 MmS2SpVv[3Srb36gRZN{[Xl? MUSyNEDPxE1? M4m4eVEhcA>? MYrzeZBxemW|c3XzJJRp\SCWR1[t{tIucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YheDR2L4C0NkBOSVBia3nuZZNmKG:{IGPBVGswUk6N NVHjS4dNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|Y6PzhpPkK2NVM3QTd6PD;hQi=>
WE-68 MUDBdI9xfG:|aYOgRZN{[Xl? NVzCU|FpOC1{NDFOwG0> NIDGfpIzPCCq MmjLbY5lfWOnczDj[YxtKGSnYYToJIlvKGSxc3Wg[IVx\W6mZX70cJk> MkH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUW4NFUoRjJ4MEW1PFA2RC:jPh?=
SK-ES-1 M2j4UWFxd3C2b4Ppd{BCe3OjeR?= M2DBZlAuOTBizszN M4LSTFI1KGh? NX3QS3hFcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHTvd4Uh\GWyZX7k[Y51dHl? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUiwOUc,OjZyNUW4NFU9N2F-
SK-N-MC  NEfWbY1CeG:ydH;zbZMhSXO|YYm= MXiwMVIvPSEQvF2= NGPSenIzPCCq M1vHUIlv\HWlZYOgZ4VtdCCmZXH0bEBqdiCmb4PlJIRmeGWwZHXueIx6 MkWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUW4NFUoRjJ4MEW1PFA2RC:jPh?=
WE-68 NUK0UZZPTnWwY4Tpc44hSXO|YYm= NUHNPI0{OjBizszN MUCwMVI1KGh? NEnKS2Ji[3SrdnH0[ZMh[2G|cHHz[UA{Nzd? NWDFOIw2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVU5ODVpPkK2NFU2QDB3PD;hQi=>
SK-ES-1 MV7GeY5kfGmxbjDBd5NigQ>? M3TGNVExKM7:TR?= MYSwMVI1KGh? NVLUdVht[WO2aY\heIV{KGOjc4Dhd4UhOy95 MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUiwOUc,OjZyNUW4NFU9N2F-
SK-N-MC  M4DCTGZ2dmO2aX;uJGF{e2G7 MYCzJO69VQ>? MXKwMVI1KGh? M2D3[4FkfGm4YYTld{Bk[XOyYYPlJFMwPw>? NFHocZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC1OVgxPSd-Mk[wOVU5ODV:L3G+
NRK-49F MYHGeY5kfGmxbjDBd5NigQ>? NVf1W2lKOOLCk{NCpO69VQ>? M3zyblM3KGh? MUPpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\iEQsT3TUWEh[W6mIH\pZpJwdmWldHnuJIRwe2ViZHXw[Y5l\W62bIm= NUj5UJdPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlIxODNpPkK2NFIzODB|PD;hQi=>
NRK-49F Mn3WSpVv[3Srb36gRZN{[Xl? M2HadlDjiJN{wrFOwG0> NYDzeoRmOzZiaB?= MWPlcohidmOnczDwbI9{eGixconsZZRqd25ib3[gSWdHWiCjbnSgVGRITlMQstMg NFTJNo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyNlAxOyd-Mk[wNlIxODN:L3G+
NRK-49F MnnwSpVv[3Srb36gRZN{[Xl? NFT5cmIx6oDVMtMg{txO M{\W[FM3KGh? MWXlcohidmOnczDTWGFVOyCyaH;zdIhwenmuYYTpc44> NV:wbo5[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlIxODNpPkK2NFIzODB|PD;hQi=>
RAW264.7 MXPGeY5kfGmxbjDBd5NigQ>? NGjhW2syKM7:TR?= NH;zXG43KGh? NHvQWVd2eHKnZ4XsZZRmeyC2aHWgdoVlfWOnZDDTTXJVOSCycn;0[YlvKG:{IH3SUmEhdGW4ZXzzJIJ6KGirZ3ig[4x2[2:|ZR?= M4XLUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{mzPVk2Lz5{NUe5N|k6PTxxYU6=
MCF10A M3nzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7DXJQxNTJyIN88US=> NIf3NZozPCCq M17QcJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M{\UZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
MCF-7 NUP4c|U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWCwMVIxKM7:TR?= NEjwUHEzPCCq MVny[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> NEiyPHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxNVM2Pid-MkW0NVE{PTZ:L3G+
T47D NHvOfndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDNSmcxNTJyIN88US=> M3HBWVI1KGh? MWry[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> NYnOOHJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
SKBR3 NHvsZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q2dFAuOjBizszN MYqyOEBp M3KzUpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NETQcGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxNVM2Pid-MkW0NVE{PTZ:L3G+
MDA-MB-231 MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqwMVIxKM7:TR?= NUe3W5R4OjRiaB?= MXfy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> NF\oS249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxNVM2Pid-MkW0NVE{PTZ:L3G+
SUM149 M3zjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYiwMVIxKM7:TR?= NGX5[pQzPCCq NH;JcG1z\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
HS578T M{OyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjIW4sxNTJyIN88US=> MnXFNlQhcA>? MU\y[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
BT20 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlT1NE0zOCEQvF2= NH71eWUzPCCq MkXkdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M{LWeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
A459 M{XtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKwMVIxKM7:TR?= MkPoNlQhcA>? MVfy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> M2fjSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
HCT116 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj6WHYxNTJyIN88US=> M3nCeVI1KGh? NVnmbnlNemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NED5OFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxNVM2Pid-MkW0NVE{PTZ:L3G+
Neu MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVOwXJhEOC1{MDFOwG0> MkfDNlQhcA>? MXvy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> M{DhclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
MDA-MB-231 NIDi[odHfW6ldHnvckBCe3OjeR?= NH3n[Fk2KM7:TR?= NWrSV3VmQCCq MX\pcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCjY3nkbYMhfmW|aXP1cIFzKG:{Z3Hu[Yxt\XN? M{P0VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
MDA-MB-231 MlfiSpVv[3Srb36gRZN{[Xl? MYW1JO69VQ>? NGnKbYcyPiCq M{nSZYlv\HWlZYOgcJl{d3OxbXHsJI1mdWK{YX7lJJBmem2nYXLpcIl7[XSrb36= MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
MC3T3-E1 NIH6NJpHfW6ldHnvckBCe3OjeR?= M1GzZ|ExKM7:TR?= NH3nSm03OCCvaX9CpC=> NWC1WYlie3WycILld5NmeyC2aHWgSmdHNTJvc4TpcZVt[XSnZDDvd5Rmd3C{b4Tl[4VzcW5icnXs[YF{\Q>? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7MEC5OUc,OjV{OUCwPVU9N2F-
MC3T3-E1 MYTGeY5kfGmxbjDBd5NigQ>? NH;CTG0yOCEQvF2= MXm2NEBucW8EoB?= MkLXZZR1\W63YYTld{B1cGViRlfGMVIucW6mdXPl[EBwe3Snb4Dyc5Rm\2W{aX6gcXJPSSCneIDy[ZN{cW:w MnjEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OUCwPVUoRjJ3MkmwNFk2RC:jPh?=
MC3T3-E1 MYnGeY5kfGmxbjDBd5NigQ>? NWPie5JlOTBizszN NHWw[mE3OCCvaX9CpC=> MmjCZZR1\W63YYTld{B1cGViRlfGMVIucW6mdXPl[EBwe3Snb4Dyc5Rm\2W{aX6gcXJPSSCneIDy[ZN{cW:w Mnj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OUCwPVUoRjJ3MkmwNFk2RC:jPh?=
MC3T3-E1 NHH5OGdHfW6ldHnvckBCe3OjeR?= M{DHUVExKM7:TR?= M1vjVlYxKG2rbtMg MYjzeZBxemW|c3XzJJRp\SCETWCtOE1{fGmvdXzheIVlKF[HR1[gdoVt\WG|ZR?= MnXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{W0OFQoRjJ2NEO1OFQ1RC:jPh?=
MC3T3-E1 NVLw[VlOTnWwY4Tpc44hSXO|YYm= NE\SSXoyOCEQvF2= MXu2NEBucW8EoB?= NIXZ[WF{fXCycnXzd4V{KHSqZTDQS2Yz|rFvc4TpcZVt[XSnZDDPVGchemWuZXHz[S=> NIHpN4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOzN|M{Pid-MkSzN|M{OzZ:L3G+
MC3T3-E1 M2e0PWZ2dmO2aX;uJGF{e2G7 NG\HNpAyOCEQvF2= NVnNOFN{PjBibXnuxsA> MVvy[YR2[2W|IITo[UBRT0Z{zsGtd5RqdXWuYYTl[EBxcG:|cHjvdplt[XSrb36gc4YheDR2L4C0NkBOSVBia3nuZZNm NFOyNnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOzN|M{Pid-MkSzN|M{OzZ:L3G+
MC3T3-E1 NGS5eHhHfW6ldHnvckBCe3OjeR?= MY[xNEDPxE1? MUS2NEBucW8EoB?= MWrheJRmdnWjdHXzJJRp\SCSR1[y{tEucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4Yh[m:2aDDNSWsyNzJiYX7kJHJi\i1z MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN|M{OzOkc,OjR|M{OzN|Y9N2F-
RPE M2\a[WNmdGxiVnnhZoltcXS7IFHzd4F6 MYq1JOK2VQ>? MV2xJIg> M1jiNIF1fGWwdXH0[ZMhV0IQsj3pcoR2[2WmIHTlZ5Jm[XOnIH;mJINmdGxidnnhZoltcXS7 M4Hp[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEO2PVM5Lz5{NECzOlk{QDxxYU6=
9607 MYDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWOxJO69VQ>? NUfEXo9wOzZiaB?= NE\CdXpqdmO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxbYDhdoVlKHerdHigcYVt[XSxbnnuJIFtd26n MnXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mk[5OFkoRjJ|N{K2PVQ6RC:jPh?=
9607 NEPrXXZHfW6ldHnvckBCe3OjeR?= MkLINUDPxE1? NVfWbWdDOzZiaB?= M17QW4lv[3KnYYPld{BUUVKWMTDhcoQh\GWlcnXhd4VlKGGlZYT5cIF1\WRvcEWzJIV5eHKnc4Ppc44> NIjmPJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyOlk1QSd-MkO3NlY6PDl:L3G+
RPMI.8226 M{PqW2NmdGxiVnnhZoltcXS7IFHzd4F6 NFLrZWM4NzFyIN88US=> M4W3dVI1KGh? NVq0ZWpD\GWlcnXhd4V{KH[rYXLpcIl1gSClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 MmPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUC3NlgoRjJzOUWwO|I5RC:jPh?=
U266 MmnQR4VtdCCYaXHibYxqfHliQYPzZZk> MX[3M|ExKM7:TR?= NG[0OZkzPCCq MXHk[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= NELufnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1NFczQCd-MkG5OVA4Ojh:L3G+
MM.1S M4rk[GNmdGxiVnnhZoltcXS7IFHzd4F6 M13oUVcwOTBizszN MUmyOEBp MWnk[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3MEeyPEc,OjF7NUC3Nlg9N2F-
KMS12 M1nVTmNmdGxiVnnhZoltcXS7IFHzd4F6 MXu3M|ExKM7:TR?= M13RfFI1KGh? MmDP[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3MEeyPEc,OjF7NUC3Nlg9N2F-
LR5 NVv4T|BES2WubDDWbYFjcWyrdImgRZN{[Xl? M2X6WVcwOTBizszN M2n1RVI1KGh? NFL6dGVl\WO{ZXHz[ZMhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> MmrZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUC3NlgoRjJzOUWwO|I5RC:jPh?=
MM.1R MlrRR4VtdCCYaXHibYxqfHliQYPzZZk> NGDINFU4NzFyIN88US=> MVOyOEBp Ml34[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 M2qxNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUWwO|I5Lz5{MUm1NFczQDxxYU6=
Ina6 M2TpWGNmdGxiVnnhZoltcXS7IFHzd4F6 NHvIO5A4NzFyIN88US=> M3rzXVI1KGh? NWfOXJp6\GWlcnXhd4V{KH[rYXLpcIl1gSClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3MEeyPEc,OjF7NUC3Nlg9N2F-
RPMI-8226 MoHFRZBweHSxc3nzJGF{e2G7 MWG3M|ExKM7:TR?= MX2yOEBp MUnpcoR2[2W|IHGgd4lodmmoaXPhcpQhcW6lcnXhd4UhcW5idHjlJGFvdmW6aX6gWkswWEokiKNCpIFxd3C2b4Ppdy=> NFHqbWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1NFczQCd-MkG5OVA4Ojh:L3G+
MM.1R  MV\BdI9xfG:|aYOgRZN{[Xl? NH;D[oQ4NzFyIN88US=> NGroc5kzPCCq NX7KOZNYcW6mdXPld{BiKHOrZ37p[olk[W62IHnuZ5Jm[XOnIHnuJJRp\SCDbn7lfIlvKFZtL2DJ5qiTyqCjcH;weI9{cXN? MlviQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUC3NlgoRjJzOUWwO|I5RC:jPh?=
H411EC3 M1Hze2Z2dmO2aX;uJGF{e2G7 NUi1d2tXPTBxMUCwJI5O M1uyd|YhcA>? MnvmbY5kemWjc3XzJHNKWlRzIHHjeIl3cXS7IHnuJJRp\SCycnXz[Y5k\SCxZjDUV2EtKFCHUFPLJIFkfGm4aYT5MEBuWk6DIHzleoVteyCxZjDQZ4syKGGwZDDQ[4My|rFuIHHu[EBmdGW4YYTpcoch\2y3Y3;z[UBxem:mdXP0bY9v MlvzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MUKwPVYoRjJzMkGyNFk3RC:jPh?=
hepatocytes MWDGeY5kfGmxbjDBd5NigQ>? NX75blZtOTBibl2= NXrXNJFqPiCq MWjpcoNz\WG|ZYOgV2lTXDFiYXP0bZZqfHliaX6geIhmKHC{ZYPlcoNmKG:oIGTTRUwhWEWSQ1ugZYN1cX[rdImsJI1TVkFibHX2[Yx{KG:oIGDjb|Eh[W6mIGDnZ|HPuSxiYX7kJIVt\X[jdHnu[{BodHWlb4PlJJBzd2S3Y4Tpc44> M33GWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkGyNFk3Lz5{MUKxNlA6PjxxYU6=
hepatocytes NV6yTlB6TnWwY4Tpc44hSXO|YYm= NX3TUHRjOTBibl2= MVG2JIg> NGnWNlJqdmO{ZXHz[ZMhUG2pY4NCpIFv\MLiQXPjxsBo\W6nIHX4dJJme3Orb36= NV7w[FdKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNVIxQTZpPkKxNlEzODl4PD;hQi=>
U2OS MYXGeY5kfGmxbjDhd5NigQ>? MYiwMlExKHWP Mn3YRYN1cX[jdHnvckBw\iCVSWLUNUBqdiCqdX3hckBWOk:VIHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJJA2OyCmZXHj[ZR6dGG2aX;uJIxmfmWuIHH0JFAvOTBidV2= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDB2NkSwPUc,OThyNE[0NFk9N2F-
A673 Mn70dWhVWyCjc4PhfS=> MUjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? NH7MPYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
DAOY NH;wfIlyUFSVIHHzd4F6 NF61dVdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 MUjxTHRUKGG|c3H5 NUTyO3UyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz NUL0NYNFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD MnjZdWhVWyCjc4PhfS=> NFzYW41yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN? NEnnUpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) NYXL[|RPeUiWUzDhd5NigQ>? MnrRdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| MlHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 NXvPN4FPeUiWUzDhd5NigQ>? MmfudWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= NYf0UW1MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 M4LWU5FJXFNiYYPzZZk> MnOxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= NX62[lRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 NYDCSYRQeUiWUzDhd5NigQ>? Mm\wdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? MlruQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh30 MXPxTHRUKGG|c3H5 MXLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh|MDDj[Yxtew>? M{XuOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 NVHMXHZ7eUiWUzDhd5NigQ>? MXnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? NGHWOIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh18 NIK0ZpNyUFSVIHHzd4F6 NW[yVVN4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO= NHLBdnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Assay
Methods Test Index PMID
Western blot Cleaved-PARP-1 / Cleaved-caspase-3 / LC3-II / p62 / SIRT1 26655844
Immunofluorescence Cathepsin B 26655844
Growth inhibition assay Cell viability 25411356
In vivo In DIO mice SRT1720 mimics several of the effects observed after calorie restriction including improved insulin sensitivity, normalized glucose and insulin levels, and increased mitochondrial capacity. In addition, in diet-induced obese and genetically obese mice, SRT1720 improves insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes. Consistent with improved glucose tolerance, the glucose infusion rate required to maintain euglycaemia is approximately 35% higher in SRT1720-treated fa/fa rats, and the total glucose disposal rate is increased by approximately 20%. [1] SRT1720 also prevents multiple myeloma tumor growth. SRT1720 increases the cytotoxic activity of bortezomib or dexamethasone. [2]

Protocol (from reference)

Kinase Assay:[1]
  • SIRT1 fluorescence polarization assay:

    In the SIRT1 FP assay, SIRT1 activity is monitored using a 20 amino acid peptide (Ac-Glu-Glu-Lys(biotin)-Gly-Gln-Ser-Thr-Ser-Ser-His-Ser-Lys(Ac)-Nle-Ser-Thr-Glu-Gly–Lys(MR121 or Tamra)-Glu-Glu-NH2) derived from the sequence of p53. The peptide is N-terminally linked to biotin and C-terminally modified with a fluorescent tag. The reaction for monitoring enzyme activity is a coupled enzyme assay where the first reaction is the deacetylation reaction catalyzed by SIRT1 and the second reaction is cleavage by trypsin at the newly exposed lysine residue. The reaction is stopped and streptavidin is added in order to accentuate the mass differences between substrate and product. The sensitivity of the FP assay allows identification of SRT1720. The fluorescence polarization reaction conditions are as follows: 0.5 μM peptide substrate, 150 μM βNAD+, 0-10 nM SIRT1, 25 mM Tris-acetate pH 8, 137 mM Na-Ac, 2.7 mM K-Ac, 1 mM Mg-Ac, 0.05% Tween-20, 0.1% Pluronic F127, 10 mM CaCl 2, 5 mM DTT, 0.025% BSA, and 0.15 mM nicotinamide. The reaction is incubated at 37 °C and stopped by addition of nicotinamide, and trypsin is added to cleave the deacetylated substrate. This reaction is incubated at 37 °C in the presence of 1 μM streptavidin. Fluorescent polarization is determined at excitation (650 nm) and emission (680 nm) wavelengths.

Cell Research:[2]
  • Cell lines: Human vascular endothelial cells (HUVECs)
  • Concentrations: 5 μM
  • Incubation Time: 2 hours
  • Method: Transwell Insert Assays are utilized to measure migration. In vitro angiogenesis is assessed by Matrigel capillary-like tube structure formation assay. For endothelial tube formation assay, human vascular endothelial cells (HUVECs) are obtained from Clonetics and maintained in endothelial cell growth medium-2 containing 5% FBS. After three passages, HUVEC cell viability is measured with the trypan blue exclusion assay, and <5% of cell death is observed with SRT1720 treatment.
Animal Research:[1]
  • Animal Models: Chase-SCID mice with MM.1S cells
  • Dosages: 200 mg/kg
  • Administration: Orally

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 506.02
Formula

C25H23N7OS.HCl

CAS No. 1001645-58-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
How can we prepare Srt1720 for in vivo mouse studies?

Answer:
SRT1720 HCl can be dissolved in 30% PEG 400+0.5% Tween 80+5% Propylene glycol at 30mg/ml as a suspension. It is fine for oral gavage. And we’ve also found that it can be dissolved in 2% DMSO+30% PEG 300+1%Tween 80+ddH2O at 3mg/ml clearly, which could be used for injection. When prepare the solution, please dissolve the compound in DMSO clearly first, then add PEG and Tween. After they mixed well, dilute with water.

Tags: buy SRT1720 HCl | SRT1720 HCl supplier | purchase SRT1720 HCl | SRT1720 HCl cost | SRT1720 HCl manufacturer | order SRT1720 HCl | SRT1720 HCl distributor